Twist Bioscience (NASDAQ:TWST) Stock Price Down 5.2%

Twist Bioscience Co. (NASDAQ:TWST) shares were down 5.2% on Tuesday . The company traded as low as $46.28 and last traded at $46.41. Approximately 304,156 shares changed hands during mid-day trading, a decline of 71% from the average daily volume of 1,045,244 shares. The stock had previously closed at $48.93.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on TWST shares. Evercore ISI increased their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Scotiabank upped their price objective on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday, May 6th. Guggenheim began coverage on Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. Barclays increased their target price on Twist Bioscience from $45.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, June 28th. Finally, TD Cowen increased their target price on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $48.50.

Twist Bioscience Stock Up 1.4 %

The firm has a 50 day moving average of $44.89 and a two-hundred day moving average of $38.64. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of -14.29 and a beta of 1.80.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05. The business had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. Twist Bioscience’s revenue was up 25.1% compared to the same quarter last year. During the same period last year, the firm posted ($1.06) earnings per share. Sell-side analysts forecast that Twist Bioscience Co. will post -3.08 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 4,163 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the completion of the transaction, the chief executive officer now directly owns 509,986 shares in the company, valued at $18,935,780.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Twist Bioscience news, CEO Emily M. Leproust sold 4,163 shares of the stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $154,572.19. Following the completion of the transaction, the chief executive officer now directly owns 509,986 shares in the company, valued at $18,935,780.18. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 2,408 shares of the stock in a transaction dated Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $123,602.64. Following the completion of the transaction, the chief executive officer now owns 507,578 shares of the company’s stock, valued at $26,053,978.74. The disclosure for this sale can be found here. Insiders have sold 17,246 shares of company stock valued at $706,593 over the last ninety days. 3.92% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently made changes to their positions in the stock. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience during the fourth quarter worth about $30,000. Federated Hermes Inc. bought a new position in shares of Twist Bioscience during the third quarter worth about $29,000. Headlands Technologies LLC bought a new position in shares of Twist Bioscience during the first quarter worth about $124,000. GAMMA Investing LLC raised its position in shares of Twist Bioscience by 1,896.8% during the second quarter. GAMMA Investing LLC now owns 3,754 shares of the company’s stock worth $185,000 after acquiring an additional 3,566 shares during the last quarter. Finally, International Assets Investment Management LLC raised its position in shares of Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after acquiring an additional 3,907 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.